Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Ginkgo and Improved Geriatric Rating

Safety in these studies

Overall tolerabilityNo significant difference
No differences between EGb 761 treatment and placebo were seen with regard to the rates of adverse events.
from: Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impair
Overall tolerabilityReported
The drug was safe and well tolerated.
from: Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impair

1 of 1 paper

Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
- 2023-03-23
- Review · n = 946
- Neuropsychiatric disease and treatment 19
- - Jakub Hort
  - Thomas Duning
  - Robert Hoerr
- PubMed: 36994422
- DOI: 10.2147/ndt.s401231
10 Insights on
- Improved Geriatric Rating
- High evidence
- Clinical
geriatric rating scales (1 of 2 studies)
Effect
Neutral
Effect size
Small
Significant
No